发布求助
文献互助 智能选刊 最新文献

Leukemia & Lymphoma最新文献

筛选
英文 中文
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis. 布鲁顿酪氨酸激酶抑制剂（BTKi）共价后复发/难治套细胞淋巴瘤（r/r MCL）未满足的需求：系统文献综述和荟萃分析。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-08 DOI: 10.1080/10428194.2024.2369653
James J Wu, Sally W Wade, Taha Itani, Jean-Gabriel Castaigne, Ioana Kloos, Weimin Peng, Steve Kanters, Michael J Zoratti, Martin Dreyling, Bijal Shah, Michael Wang
{"title":"Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.","authors":"James J Wu, Sally W Wade, Taha Itani, Jean-Gabriel Castaigne, Ioana Kloos, Weimin Peng, Steve Kanters, Michael J Zoratti, Martin Dreyling, Bijal Shah, Michael Wang","doi":"10.1080/10428194.2024.2369653","DOIUrl":"10.1080/10428194.2024.2369653","url":null,"abstract":"<p><p>To quantify the clinical unmet need of r/r MCL patients who progress on a covalent Bruton tyrosine kinase inhibitor (BTKi), we conducted a systematic review to identify studies that reported overall survival (OS), progression-free survival (PFS), or response outcomes of patients who received a chemo(immunotherapy) ± targeted agent standard therapy (STx) or brexucabtagene autoleucel (brexu-cel) in the post-BTKi setting. Twenty-six studies (23 observational; three trials) reporting outcomes from 2005 to 2022 were included. Using two-stage frequentist meta-analyses, the estimated median PFS/OS for patients treated with an STx was 7.6 months (95% CI: 3.9-14.6) and 9.1 months (95% CI: 7.3-11.3), respectively. The estimated objective response rate (ORR) was 45% (95% CI: 34-57%). For patients treated with brexu-cel, the estimated median PFS/OS was 14.9 months (95% CI: 10.5-21.0) and 32.1 months (95% CI: 25.2-41.2), with a pooled ORR of 89% (95% CI: 86-91%). Our findings highlight a significant unmet need for patients whose disease progresses on a covalent BTKi.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High red cell mass and high plasma volume are independently associated with thrombotic risk in polycythemia vera. 高红细胞质量和高血浆容量与多发性红细胞症的血栓风险有独立关联。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-06-20 DOI: 10.1080/10428194.2024.2368639
Ivan Krecak, Danijela Lekovic, Andrija Bogdanovic, Marko Lucijanic
{"title":"High red cell mass and high plasma volume are independently associated with thrombotic risk in polycythemia vera.","authors":"Ivan Krecak, Danijela Lekovic, Andrija Bogdanovic, Marko Lucijanic","doi":"10.1080/10428194.2024.2368639","DOIUrl":"10.1080/10428194.2024.2368639","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141427114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma. 套细胞淋巴瘤自体干细胞移植长期随访的重要性。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-05 DOI: 10.1080/10428194.2024.2373323
Colin Stewart, Carolyn Owen, Neil Chua, Anthea Peters, Mona Shafey, Alex Balogh, Jeffrey Cao, Douglas Stewart, Robert Puckrin
{"title":"Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma.","authors":"Colin Stewart, Carolyn Owen, Neil Chua, Anthea Peters, Mona Shafey, Alex Balogh, Jeffrey Cao, Douglas Stewart, Robert Puckrin","doi":"10.1080/10428194.2024.2373323","DOIUrl":"10.1080/10428194.2024.2373323","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy. 3b 期 VENICE II 试验的最新生活质量数据：接受 Venetoclax 单药治疗的复发性或难治性慢性淋巴细胞白血病患者。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2023-08-25 DOI: 10.1080/10428194.2023.2247511
Tara Cochrane, Alicia Enrico, David Gomez-Almaguer, Evgueniy Hadjiev, Ewa Lech-Maranda, Tamas Masszi, Eugene Nikitin, Tadeusz Robak, Robert Weinkove, Shang-Ju Wu, Beenish S Manzoor, Todd Busman, Madhavi Pai, Viktor Komlosi, Mary Ann Anderson
{"title":"Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy.","authors":"Tara Cochrane, Alicia Enrico, David Gomez-Almaguer, Evgueniy Hadjiev, Ewa Lech-Maranda, Tamas Masszi, Eugene Nikitin, Tadeusz Robak, Robert Weinkove, Shang-Ju Wu, Beenish S Manzoor, Todd Busman, Madhavi Pai, Viktor Komlosi, Mary Ann Anderson","doi":"10.1080/10428194.2023.2247511","DOIUrl":"10.1080/10428194.2023.2247511","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10070331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia. 依达比星和阿糖胞苷联合或不联合米哚妥林治疗 FLT3 突变的急性髓性白血病。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-07 DOI: 10.1080/10428194.2024.2373324
Kendall Diebold, Garrett Bourne, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy
{"title":"Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia.","authors":"Kendall Diebold, Garrett Bourne, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy","doi":"10.1080/10428194.2024.2373324","DOIUrl":"10.1080/10428194.2024.2373324","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular mortality among patients with diffuse large B-cell lymphoma: a population-based study. 弥漫大 B 细胞淋巴瘤患者的心血管死亡率：一项基于人群的研究。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-06-11 DOI: 10.1080/10428194.2024.2364830
Danhua Hong, Mengzhuo Yin, Jie Li, Zhiyong Deng, Zhilei Ren, Yun Zhou, Shuijin Huang, Xuejun Yan, Weijie Zhong, Feng Liu, Chongzhe Yang
{"title":"Cardiovascular mortality among patients with diffuse large B-cell lymphoma: a population-based study.","authors":"Danhua Hong, Mengzhuo Yin, Jie Li, Zhiyong Deng, Zhilei Ren, Yun Zhou, Shuijin Huang, Xuejun Yan, Weijie Zhong, Feng Liu, Chongzhe Yang","doi":"10.1080/10428194.2024.2364830","DOIUrl":"10.1080/10428194.2024.2364830","url":null,"abstract":"<p><p>We aim to investigate cardiovascular mortality risk among diffuse large B-cell lymphoma (DLBCL) patients and explore cardiovascular mortality trends in the past decades in United States. We extracted data from the Surveillance, Epidemiology, and End Results database for adult patients diagnosed with DLBCL between 1975 and 2019. Standardized mortality ratio, joinpoint regression analysis, and competing risk model were analyzed. Overall, 49,918 patients were enrolled, of whom 4167 (8.3%) cardiovascular deaths were observed, which was 1.22 times the number expected (95%CI, 1.19-1.26). During 1985-2019, the incidence-based cardiovascular mortality rate increased by 0.98% per year (95%CI, 0.58-1.39%), with statistically significant increases in age groups younger than 75 years. The cumulative mortality from cardiovascular disease increased by age but never exceeded that from DLBCL. Older age, male sex, earlier year of diagnosis, lower tumor stage at diagnosis, chemotherapy, radiotherapy, and surgery were all poor prognostic factors for cardiovascular mortality.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141306214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can the radiation dose be safely reduced in the treatment of nk/T cell lymphoma? 在治疗 nk/T 细胞淋巴瘤时，能否安全地减少放射剂量？
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-05 DOI: 10.1080/10428194.2024.2370433
Ximei Zhang, Yanlan Chai, Wei Li, Peiqi Zhao, Huilai Zhang, Peiguo Wang
{"title":"Can the radiation dose be safely reduced in the treatment of nk/T cell lymphoma?","authors":"Ximei Zhang, Yanlan Chai, Wei Li, Peiqi Zhao, Huilai Zhang, Peiguo Wang","doi":"10.1080/10428194.2024.2370433","DOIUrl":"10.1080/10428194.2024.2370433","url":null,"abstract":"<p><p>The aim of this study is to investigate the feasibility and safety of dose reduction in the radiotherapy of NK/T-cell lymphoma. A retrospective collection of clinical and treatment data was conducted on 41 patients. The analysis aimed to assess whether the reduction in radiation therapy dosage affected patients' local control and survival. Among the 41 patients, all achieved complete remission after the initial treatment. With a median follow-up of 28.4 months, all except one patient demonstrated good control within the irradiated area. In the entire cohort, a total of 6 patients died and none of the deaths were caused by local tumor failure. The 3-year overall survival rate and progression-free survival rate was 83.8%, 94.4%, respectively. The incidence of long-term toxicity was low. It seems safe to reduce the prophylactic radiation dose to 45 Gy and the preliminary treatment results are satisfactory, with further reduction in side effects.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice. 多发性骨髓瘤中的虚弱测量方法：评估临床试验和实际操作对疗效和生活质量的影响。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-10-28 DOI: 10.1080/10428194.2024.2419375
Matthew J Pianko, Hira S Mian, Kelly L Schoenbeck, Tanya M Wildes
{"title":"Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice.","authors":"Matthew J Pianko, Hira S Mian, Kelly L Schoenbeck, Tanya M Wildes","doi":"10.1080/10428194.2024.2419375","DOIUrl":"https://doi.org/10.1080/10428194.2024.2419375","url":null,"abstract":"<p><p>Multiple myeloma is a hematologic malignancy that predominantly affects older individuals, in whom frailty is prevalent. Frailty is a clinical syndrome characterized by decreased reserve and increased vulnerability to stressors, leading to decreased functional capacity. Frailty is prevalent in older individuals and negatively impacts treatment outcomes. In this review, we summarize the tools and strategies used to assess frailty in patients with multiple myeloma, review data describing treatment outcomes in frail adults with multiple myeloma using clinical trial and real-world evidence and evaluate the potential relationship of frailty with quality of life and patient-reported outcomes during therapy for multiple myeloma. Frailty-adapted therapy for MM has the potential to improve treatment outcomes for older adults with myeloma.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies. 急性髓性白血病的适应性细胞疗法：当前形势与新兴策略。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-10-25 DOI: 10.1080/10428194.2024.2414112
Serena Tharakan, Douglas Tremblay, Jacques Azzi
{"title":"Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies.","authors":"Serena Tharakan, Douglas Tremblay, Jacques Azzi","doi":"10.1080/10428194.2024.2414112","DOIUrl":"https://doi.org/10.1080/10428194.2024.2414112","url":null,"abstract":"<p><p>Efforts to produce adoptive cell therapies in AML have been largely unfruitful, despite the success seen in lymphoid malignancies. Identifying targetable antigens on leukemic cells that are absent on normal progenitor cells remains a major obstacle, as is the hostile tumor microenvironment created by AML blasts. In this review, we summarize the challenges in the development of adoptive cell therapies such as CAR-T, CAR-NK, and TCR-T cells in AML, discussing both autologous and allogeneic therapies. We also discuss methods to address myelotoxicity associated with these therapies, including rapidly switchable CAR platforms and CRISPR-Cas9 genetic engineering of hematopoietic stem cells. Finally, we present the current clinical landscape in these areas, along with future directions in the field.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma. 在复发/难治性边缘区淋巴瘤中，扎鲁替尼 (MAGNOLIA, BGB-3111-AU-003) 与伊布替尼 (PCYC-1121) 和利妥昔单抗 (CHRONOS-3) 的匹配调整间接比较。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2024-10-24 DOI: 10.1080/10428194.2024.2416577
Catherine Thieblemont, Björn E Wahlin, Leyla Mohseninejad, Kaijun Wang, Ina Zhang, Sam Keeping, Keri Yang, Pier L Zinzani
{"title":"Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma.","authors":"Catherine Thieblemont, Björn E Wahlin, Leyla Mohseninejad, Kaijun Wang, Ina Zhang, Sam Keeping, Keri Yang, Pier L Zinzani","doi":"10.1080/10428194.2024.2416577","DOIUrl":"https://doi.org/10.1080/10428194.2024.2416577","url":null,"abstract":"<p><p>In the absence of head-to-head randomized trials, unanchored matching-adjusted indirect comparisons were conducted to estimate the relative efficacy of zanubrutinib versus ibrutinib and zanubrutinib versus rituximab in relapsed or refractory marginal zone lymphoma (MZL). Logistic propensity score models were used to estimate weights for the patient-level data from two phase II single-arm trials, MAGNOLIA and BGB-3111-AU-003, such that their characteristics matched the ibrutinib and rituximab aggregate-level data from PCYC-1121 and CHRONOS-3, respectively. The base case model for each comparison incorporated four key prognostic factors: prior lines of therapy, MZL subtype, response to prior therapy, and age. A sensitivity analysis incorporating additional prognostic factors was also conducted for the ibrutinib comparison. The impact of each covariate was explored <i>via</i> a leave-one-out analysis. Compared with ibrutinib and rituximab, zanubrutinib demonstrated significant benefits in terms of both overall response and progression-free survival in patients with previously treated MZL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信